Recombinant IFN-α2a-NGR
重组人干扰素α2a与肿瘤血管特异性结合多肽NGR融合蛋白
Report date: 2022/01/14 13:23:58
Base Information
Drug NameRecombinant IFN-α2a-NGR
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (IND)
Highest Status in ChinaPending
Originator CompaniesFourth Military Medical University Of Chinese People'S Liberation Army
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesN/A
Inactive CompaniesShaanxi Jiuzhou Biotechnology Co Ltd
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A